NEW YORK (GenomeWeb) – Myriad Genetics reported after the close of the market on Tuesday that its fiscal second quarter revenues increased 15 percent year over year, driven by growth in the hereditary cancer segment and expanding prenatal testing busin
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.